Heads Up: Combat Text Neck Syndrome with Easy Tips
October 23, 2018

In today’s fast paced world, digital forms of communication are gaining pace over conventional methods. While most people use cell phones for varied reasons, chances are that slouching to a mobile phone can lead to several disorders.

“Recently, I visited a patient who complained of severe upper back pain. He woke up and was experiencing severe, acute, upper back muscle strain."...

ResMed Wins German Patent Infringement Case Against Fisher & Paykel
October 23, 2018

(AETOS Wire)-- ResMed (NYSE: RMD) (ASX: RMD), the world’s leading tech-driven medical company and innovator in sleep apnea and respiratory care, today announced the results of a court and patent office ruling in Germany in ResMed’s favor.

A trial court ruling from the Munich District Court states that the headgear used on two Fisher &"...

Philip Morris International Launches Next Generation of IQOS, the World’s Leading Heated Tobacco Product
October 23, 2018

(AETOS Wire)-- In its passion and drive to provide better choices to people who smoke, Philip Morris International Inc. (“PMI”) (NYSE: PM), the global leader in smoke-free innovation and science, has launched the next generation of IQOS. The new IQOS 3 and IQOS 3 MULTI integrate extensive consumer insights and feedback to improve design and user experience while maintaining signature taste, sensory attributes and"...

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
October 23, 2018

(AETOS Wire) -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor.......

Young Saudi treks on the Hijrah route to spread breast cancer message
October 22, 2018

ASFAN — Carrying the slogan “Walk With Her”, Yasser Al-Humaid has begun walking from Makkah to Madinah on Tuesday to enlighten women about the necessity of early examination for breast cancer.

Al-Humaid reached Asfan on Friday and met with members of the community who came to support his initiative.

Following the reception, Al-Humaid continued his journey to Madinah where he is due to arrive on Oct. 27 to highlight the"...

Outline of New ESMO Guidelines Indicates Inclusion of FOTIVDA®▼ (Tivozanib) for Patients with Advanced Renal Cell Carcinoma
October 22, 2018

(AETOS Wire) -- EUSA Pharma (EUSA) welcomes the news that FOTIVDA®▼ (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology (ESMO) clinical practice guidelines for advanced renal cell carcinoma (aRCC), anticipated to be published at the end of this year.1

The outline of the new proposed guidelines was presented"...

Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
October 22, 2018

(AETOS Wire) -- Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis (UC) who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous (IV) induction therapy. At week 52, a statistically significant proportion of patients receiving vedolizumab SC achieved clinical remission** compared to patients receiving placebo (46.2% vs. 14.3%; p<0.001). A similar rate of clinical remission was observed in the vedolizumab IV reference arm (42.6%). These results were presented at the 2018 United European Gastroenterology (UEG) Week congress in Vienna, Austria. “The VISIBLE 1 results highlight that the investigational subcutaneous......

Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC
October 19, 2018

(AETOS Wire)-- Boehringer Ingelheim today announced results from GioTag, a real-world retrospective study which examined the impact of first-line Giotrif®/Gilotrif® (afatinib) followed by osimertinib, in epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC) patients with acquired T790M mutations, the most common mechanism of resistance to first- and second-generation EGFR tyrosine"...

Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc
October 19, 2018

(AETOS Wire)-- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

Takeda Pharmaceutical Company Limited (“Takeda”) announces that it has received unconditional clearance from the Japan Fair Trade"...

Edu Min shelves health plan for teachers
October 18, 2018

RIYADH — The Ministry of Education has announced the file on medical insurance for teachers has been shelved until further notice as the ministry cannot find an appropriate deal from insurance companies.

The Center of Teachers’ Services (Tabjeel) contradicts itself as its director Ali Al-Minai said two weeks ago that the center was signing a contract to provide medical insurance for teachers. He also said that the only step left was for the"...